Aerpio Pharmaceuticals(AADI) - 2025 Q4 - Annual Results

PRESS RELEASE Exhibit 99.1 Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights Actively recruiting Phase 1 trials for PTK7-targeted antibody-drug conjugate (ADC) HWK-007 and MUC16- targeted ADC HWK-016 HWK-206 on track for planned IND submission in mid-2026 and Phase 1 start in Q3 Cash, cash equivalents and short-term investments balance of $145.7M at YE2025, anticipated to fund operations into 2028 MORRISTOWN, NJ, March 12, 2026 /PRNewswire/ -- Whitehawk ...